OriCiro is a pioneer of cell-free genome technology, providing a powerful tool for research and development aimed at unlocking the possibility of synthetic biology. The company’s proprietary technology focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules aiming to replace conventional cell-based methodology by not only streamlining current research processes, but also widening the scope of genomics research significantly. The company also owns a suite of genome technologies, including the assembly of DNA fragments and genome editing. Synthetic biology, through which new medicines and useful proteins can be produced more efficiently by modified and/or synthesized genomes — is developing rapidly worldwide. OriCiro’s technologies have potential markets in a variety of industries including the pharmaceutical, diagnostic, industrial biotech, food, and agricultural sectors.